Based on the current evidence and clinical observations, it could be suggested that allergic airway disease associated with eosinophilic infiltration and down-regulation of ACE2 does not represent a risk factor for COVID19 infection. Further investigations are highly needed to confirm mechanisms underlying the low prevalence of allergies and chronic inflammatory/respiratory diseases in COVID-19 patients and to clarify the clinical meaning and therapeutic consequences of eosinopenia in these patients.